Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $60.00

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price increased by Citigroup from $55.00 to $60.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. A number of other equities analysts have also recently commented on the company. Sanford C. Bernstein […]

Leave a Reply

Your email address will not be published.

Previous post Hims & Hers Health (NYSE:HIMS) Lowered to “Underperform” Rating by Bank of America
Next post HIVE Digital Technologies (NASDAQ:HIVE) Stock Price Expected to Rise, Northland Securities Analyst Says